Your email has been successfully added to our mailing list.

×
0 0 0 0 0 0 0 -0.0598130841121496
Stock impact report

RegenRx nabs Canadian patent covering active ingredient in candidate RGN-352 [Seeking Alpha]

REGENERX BIOPHARMS INC (RGRX) 
NASDAQ:AMEX Investor Relations: regenerx.com/investors
Company Research Source: Seeking Alpha
RegenRx nabs Canadian patent covering active ingredient in candidate RGN-352The Canadian Patent Officeissues a Notice of Allowance to RegeneRx Biopharmaceuticals (OTCQB:RGRX+0.1%) covering the use of Thymosin beta 4, the active ingredient in pipeline candidate RGN-352, for the treatment of neurological injury and damage.Phase 2-stageRGN-352 is designed for the systematic treatment of brain injury from stroke or trauma, CNS disorders such as peripheral neuropathy and multiple sclerosis and cardiac damage from heart attacks.Click to subscribe to real-time analytics on RGRXNow read:Novo Nordisk - Came For The Gap, Stayed For The Long Term » Show less Read more
Impact Snapshot
Event Time:
RGRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for RGRX alerts
Opt-in for
RGRX alerts

from News Quantified
Opt-in for
RGRX alerts

from News Quantified